The story of the European Randomized Study of Screening for Prostate Cancer
The rationale for the ERSPC trial
ERSPC
The Finnish trial of prostate cancer screening
ERSPC
Specific features of the Italian section of the ERSPC
The Spanish contribution to the European Randomized Study of Screening for Prostate Cancer
Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Sweden
Features and preliminary results of prostate cancer screening in Canton Aargau, Switzerland
Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands)
The Data Monitoring Committee – bridging the gap between urology and public health epidemiology
The ERSPC Quality Control Committee
Report of the Pathology Committee
Quality assessment for prostate-specific antigen (PSA) in relation to ERSPC
Determining the cause of death in randomized screening trial(s) for prostate cancer
How to improve the specificity and sensitivity of biopsy technique in screening
Four-year prostate-specific antigen progression in the non-cancer population of the European Randomized Study of Screening for Prostate Cancer
Consistency of prostate cancer grading results in screened populations across Europe
The clinical significance of a small focus of well-differentiated carcinoma at prostate biopsy
Contamination by opportunistic screening in the European Randomized Study of Prostate Cancer Screening
Including the quality-of-life effects in the evaluation of prostate cancer screening
MISCAN
Monitoring the ERSPC trial
Branding the ERSPC
European Randomized Study of Screening for Prostate Cancer
Abbreviations